140 related articles for article (PubMed ID: 12134234)
1. Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal experiments and clinical study.
Mayer J; Doubek M; Doubek J; Horký D; Scheer P; Stepánek M
J Infect Dis; 2002 Aug; 186(3):379-88. PubMed ID: 12134234
[TBL] [Abstract][Full Text] [Related]
2. Must we really fear toxicity of conventional amphotericin B in oncological patients?
Mayer J; Doubek M; Vorlìcek J
Support Care Cancer; 1999 Jan; 7(1):51-5. PubMed ID: 9926976
[TBL] [Abstract][Full Text] [Related]
3. Effects of fluid and electrolyte management on amphotericin B-induced nephrotoxicity among extremely low birth weight infants.
Holler B; Omar SA; Farid MD; Patterson MJ
Pediatrics; 2004 Jun; 113(6):e608-16. PubMed ID: 15173544
[TBL] [Abstract][Full Text] [Related]
4. Effects of hydration with salt repletion on renal toxicity of conventional amphotericin B empirical therapy: a prospective study in patients with hematological malignancies.
Girmenia C; Cimino G; Di Cristofano F; Micozzi A; Gentile G; Martino P
Support Care Cancer; 2005 Dec; 13(12):987-92. PubMed ID: 15756584
[TBL] [Abstract][Full Text] [Related]
5. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial.
Subirà M; Martino R; Gómez L; Martí JM; Estany C; Sierra J
Eur J Haematol; 2004 May; 72(5):342-7. PubMed ID: 15059069
[TBL] [Abstract][Full Text] [Related]
6. Impact of liposomal amphotericin B on renal function in critically ill patients with renal function impairment.
Alvarez-Lerma F; Soriano MC; Rodríguez M; Catalán M; Llorente AM; Vidart N; Garitacelaya M; Maraví E; Fernández E; Alvarado F; López M; Alvarez-Sánchez B; Espinosa J; Quintana E;
Rev Esp Quimioter; 2012 Sep; 25(3):206-15. PubMed ID: 22987267
[TBL] [Abstract][Full Text] [Related]
7. Amphotericin B deoxycholate (d-AMB) use in cases with febrile neutropenia and fungal infections: lower toxicity with suitable premedication.
Oto OA; Paydas S; Disel U; Yavuz S; Seydaoglu G
Mycoses; 2007 Mar; 50(2):135-9. PubMed ID: 17305778
[TBL] [Abstract][Full Text] [Related]
8. A double-blinded, placebo-controlled, multicenter clinical trial of N-acetylcysteine for preventing amphotericin B-induced nephrotoxicity.
Karimzadeh I; Khalili H; Sagheb MM; Farsaei S
Expert Opin Drug Metab Toxicol; 2015; 11(9):1345-55. PubMed ID: 26050706
[TBL] [Abstract][Full Text] [Related]
9. Potassium depletion potentiates amphotericin-B-induced toxicity to renal tubules.
Bernardo JF; Murakami S; Branch RA; Sabra R
Nephron; 1995; 70(2):235-41. PubMed ID: 7566310
[TBL] [Abstract][Full Text] [Related]
10. [Safety of long-term administration of conventional amphotericin B in oncology patients].
Doubek M; Mayer J; Horký D
Cas Lek Cesk; 2002 Mar; 141(5):156-9. PubMed ID: 11998223
[TBL] [Abstract][Full Text] [Related]
11. The evaluation of frequency of nephrotoxicity caused by liposomal amphotericin B.
Kato H; Hagihara M; Yamagishi Y; Shibata Y; Kato Y; Furui T; Watanabe H; Asai N; Koizumi Y; Mikamo H
J Infect Chemother; 2018 Sep; 24(9):725-728. PubMed ID: 29773439
[TBL] [Abstract][Full Text] [Related]
12. An experimental model of amphotericin B nephrotoxicity with renal tubular acidosis.
Gouge TH; Andriole VT
J Lab Clin Med; 1971 Nov; 78(5):713-24. PubMed ID: 5128824
[No Abstract] [Full Text] [Related]
13. Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?
Ural AU; Avcu F; Cetin T; Beyan C; Kaptan K; Nazaroglu NK; Yalcin A
Eur J Clin Pharmacol; 2002 Jan; 57(11):771-3. PubMed ID: 11868798
[TBL] [Abstract][Full Text] [Related]
14. Liposomal amphotericin B does not induce nephrotoxicity or renal function impairment in premature neonates.
Manzoni P; Galletto P; Rizzollo S; Franco C; Gallo E; Antonucci R; Fanos V; Farina D
Early Hum Dev; 2012 May; 88 Suppl 2():S86-91. PubMed ID: 22633524
[TBL] [Abstract][Full Text] [Related]
15. [Retrospective investigation on the cases treated with liposomal amphotericin B].
Yamagishi Y; Mikamo H
Jpn J Antibiot; 2010 Oct; 63(5):347-64. PubMed ID: 21268407
[TBL] [Abstract][Full Text] [Related]
16. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain.
Aguado JM; Lumbreras C; González-Vidal D;
Clin Microbiol Infect; 2004 Sep; 10(9):785-90. PubMed ID: 15355408
[TBL] [Abstract][Full Text] [Related]
17. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study.
Chamilos G; Luna M; Lewis RE; Chemaly R; Raad II; Kontoyiannis DP
Clin Ther; 2007 Sep; 29(9):1980-6. PubMed ID: 18035197
[TBL] [Abstract][Full Text] [Related]
18. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries.
Ullmann AJ; Sanz MA; Tramarin A; Barnes RA; Wu W; Gerlach BA; Krobot KJ; Gerth WC;
Clin Infect Dis; 2006 Aug; 43(4):e29-38. PubMed ID: 16838223
[TBL] [Abstract][Full Text] [Related]
19. [Must we be really concerned about amphotericin B toxicity in oncology patients?].
Mayer J; Doubek M
Cas Lek Cesk; 1998 Oct; 137(20):632-6. PubMed ID: 9863267
[TBL] [Abstract][Full Text] [Related]
20. Comparison of nephrotoxicity associated to different lipid formulations of amphotericin B: a real-life study.
Falci DR; da Rosa FB; Pasqualotto AC
Mycoses; 2015 Feb; 58(2):104-12. PubMed ID: 25590436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
